Description: Stability and Storage:The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. Detection method:Colorimetric Sample type:Plasma, Serum Assay type:Quantitative Sensitivity:0.156 μg/ml Range:0.31-5 μg/mL Recovery:80-120% Background:Emibetuzumab (as known as LY2875358) is a humanized immunoglobulin G4 monoclonal bivalent anti-MET antibody that blocks MET signaling. This drug was developed by Eli Lilly & Company and has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others. In preclinical models, emibetuzumab inhibited growth of tumors that are dependent on MET, including tumors that exhibit HGF-dependent and HGF-independent biology. Administration of a single dose of emibetuzumab resulted in continuous reduction of MET protein expression for 14 days in mouse xenografts. Emibetuzumab demonstrated dose-dependent, single-agent activity in various MET-expressing tumor models, and additive effects were observed in combination with erlotinib for reducing tumor volume in lung cancer mouse xenograft models. In Phase 1 dose escalation studies, emibetuzumab monotherapy was well tolerated in patients with advanced solid tumors, including gastric cancer, with no dose-limiting toxicities. Shipping:2-8 ℃ Specifications:Emibetuzumab Note:For Research Use Only.